Ortho Clinical Diagnostics Holdings plc (OCDX) News

Ortho Clinical Diagnostics Holdings plc (OCDX): $18.72

0.14 (+0.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter OCDX News Items

OCDX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

OCDX News Highlights

  • For OCDX, its 30 day story count is now at 9.
  • Over the past 22 days, the trend for OCDX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • PURE, DECK and OPT are the most mentioned tickers in articles about OCDX.

Latest OCDX News From Around the Web

Below are the latest news stories about Ortho Clinical Diagnostics Holdings plc that investors may wish to consider to help them evaluate OCDX as an investment opportunity.

Ortho Clinical Diagnostics Holdings (OCDX) Presents At H. C. Wainwright 23rd Annual Global Investment Conference - Slideshow

The following slide deck was published by Ortho Clinical Diagnostics Holdings plc in conjunction with this event....

SA Transcripts on Seeking Alpha | September 16, 2021

Ortho Clinical Diagnostics Announces Closing of Secondary Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares

RARITAN, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced the closing (the “Closing”) of the previously announced underwritten secondary offering of 25,300,000 of the Company’s ordinary shares held by a selling shareholder affiliated with The Carlyle Group (the “Selling Shareholder”), which includes the full exercise by the underwriters of their opt

Yahoo | September 14, 2021

Ortho Clinical Diagnostics Announces Pricing of Secondary Offering of Ordinary Shares

RARITAN, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the Company), one of the worlds largest pure-play in vitro diagnostics companies, today announced the pricing of the previously announced underwritten secondary offering of 22,000,000 of the Companys ordinary shares held by a selling shareholder affiliated with The Carlyle Group (the Selling Shareholder) at a price of $17.50 per ordinary share. The offering is expected to close on September 14, 2021, subject to customary closing conditions. The Selling Shareholder granted the underwriters a 30-day option to purchase up to 3,300,000 additional ordinary shares of the Company at the public offering price less the underwriting discount.

Intrado Digital Media | September 9, 2021

Ortho Clinical Diagnostics Announces Secondary Offering of Ordinary Shares

RARITAN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the Company), one of the worlds largest pure-play in vitro diagnostics companies, today announced that one of its shareholders (the Selling Shareholder), an affiliate of The Carlyle Group, intends to offer for sale in an underwritten secondary offering 22,000,000 ordinary shares of the Company pursuant to a registration statement filed by the Company with the U.S. Securities and Exchange Commission (the SEC). Additionally, the Selling Shareholder expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ordinary shares on the same terms and conditions.

Intrado Digital Media | September 7, 2021

Ortho Clinical Diagnostics to Participate in September Investor Conferences

RARITAN, N.J., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX ), one of the world''s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in two upcoming investor conferences: Morgan Stanley 19 th Annual Global Healthcare Conference Fireside chat scheduled for Thursday, September 9, 2021 at 2:00pm ET H.C. Wainwright 23 rd Annual Global Investment Conference Pre-recorded presentation will be available Monday, September 13, 2021 at 7:00am ET Interested parties can access a live webcast and replay of each presentation on the "Investors" page of Full story available on Benzinga.com

Benzinga | September 3, 2021

Immunodiagnostic System Market size to increase at a Sustainable Growth Rate during the Forecast Period, Key Players - Ortho-Clinical Diagnostics, Immunodiagnostic Systems (IDS), Abbott Diagnostics, DiaSorin.

The Immunodiagnostic System Market is expected to grow at a CAGR of 7.6%. The factors leading to this extraordinary growth is attributed to various market dynamics discussed in the report. Our experts have examined the market from a 360 degree

OpenPR | August 25, 2021

Global In Vitro Diagnostics (IVD) Market Industry Analysis by Market Vendors, Future Developments, Data Sources and Research Methodology by 2028||bioMérieux SA, DiaSorin, Ortho Clinical Diagnostics, Agilent Technologies Inc., QIAGEN, Bayer AG, Hologic In

Global In Vitro Diagnostics (IVD) market analysis report examines various segments that are relied upon to witness the quickest growth amid the approximate forecast frame. With the particular base year and the historic year, definite estimations and calculations are carried

OpenPR | August 19, 2021

Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.96

Shareholders might have noticed that Ortho Clinical Diagnostics Holdings plc ( NASDAQ:OCDX ) filed its quarterly result...

Yahoo | August 8, 2021

Ortho Clinical Diagnostics Holdings plc (OCDX) Q2 2021 Earnings Call Transcript

With me today to discuss our financial results are Chris Smith, Ortho's chairman and CEO; and Joe Busky, Ortho's chief financial officer. Mike Iskra, our EVP of commercial excellence and strategy, will join us on the Q&A portion of the call.

Yahoo | August 5, 2021

Ortho Clinical Diagnostics Expands COVID-19 Test Offerings with Emergency Use Authorization (EUA) of Total Nucleocapsid Antibody Test

Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its qualitative COVID-19 Total N antibody test received U.S. Food and Drug Administration EUA. This new antibody test is the fifth assay to receive EUA within Ortho's COVID-19 testing solutions. The test detects the individual's immune response or total antibodies to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or prior

Yahoo | August 5, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5765 seconds.